Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study
- PMID: 26165918
- DOI: 10.1016/j.vaccine.2015.06.105
Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study
Abstract
This serological follow up study assessed the kinetics of antibody response in children who previously participated in a single centre, open-label, randomised controlled trial of low-dose compared to standard-dose diphtheria booster preschool vaccinations in the United Kingdom (UK). Children had previously been randomised to receive one of three combination vaccines: either a combined adsorbed tetanus, low-dose diphtheria, 5-component acellular pertussis and inactivated polio vaccine (IPV) (Tdap-IPV, Repevax(®); Sanofi Pasteur MSD); a combined adsorbed tetanus, low-dose diphtheria and 5-component acellular pertussis vaccine (Tdap, Covaxis(®); Sanofi Pasteur MSD) given concomitantly with oral polio vaccine (OPV); or a combined adsorbed standard-dose diphtheria, tetanus, 2-component acellular pertussis and IPV (DTap-IPV, Tetravac(®); Sanofi Pasteur MSD). Blood samples for the follow-up study were taken at 1, 3 and 5 years after participation in the original trial (median, 5.07 years of age at year 1), and antibody persistence to each vaccine antigen measured against defined serological thresholds of protection. All participants had evidence of immunity to diphtheria with antitoxin concentrations greater than 0.01IU/mL five years after booster vaccination and 75%, 67% and 79% of children who received Tdap-IPV, Tdap+OPV and DTap-IPV, respectively, had protective antitoxin levels greater than 0.1IU/mL. Long lasting protective immune responses to tetanus and polio antigens were also observed in all groups, though polio responses were lower in the sera of those who received OPV. Low-dose diphtheria vaccines provided comparable protection to the standard-dose vaccine and are suitable for use for pre-school booster vaccination.
Keywords: Immunogenicity; Low-dose diphtheria vaccine; Pre-school booster.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.Vaccine. 2018 Apr 19;36(17):2300-2306. doi: 10.1016/j.vaccine.2018.03.021. Epub 2018 Mar 22. Vaccine. 2018. PMID: 29576304 Clinical Trial.
-
Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children.Vaccine. 2004 Oct 22;22(31-32):4262-9. doi: 10.1016/j.vaccine.2004.04.027. Vaccine. 2004. PMID: 15474717 Clinical Trial.
-
Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.Vaccine. 2015 May 21;33(22):2594-601. doi: 10.1016/j.vaccine.2015.03.104. Epub 2015 Apr 14. Vaccine. 2015. PMID: 25882172 Clinical Trial.
-
New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Ann Pharmacother. 2010. PMID: 20197476 Review.
-
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.Drugs. 2012 Sep 10;72(13):1765-91. doi: 10.2165/11209630-000000000-00000. Drugs. 2012. PMID: 22931522 Review.
Cited by
-
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors.Cells. 2020 Jul 19;9(7):1727. doi: 10.3390/cells9071727. Cells. 2020. PMID: 32707692 Free PMC article. Review.
-
Immune persistence after pertussis vaccination.Hum Vaccin Immunother. 2017 Apr 3;13(4):744-756. doi: 10.1080/21645515.2016.1259780. Epub 2017 Jan 3. Hum Vaccin Immunother. 2017. PMID: 28045580 Free PMC article. Review.
-
Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.Dig Dis Sci. 2018 Jun;63(6):1532-1540. doi: 10.1007/s10620-018-5043-2. Epub 2018 Mar 29. Dig Dis Sci. 2018. PMID: 29594970
-
Use of tetanus-diphtheria (Td) vaccine in children 4-7 years of age: World Health Organization consultation of experts.Vaccine. 2020 May 6;38(21):3800-3807. doi: 10.1016/j.vaccine.2020.01.018. Epub 2020 Jan 23. Vaccine. 2020. PMID: 31983584 Free PMC article.
-
Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP): Recommended Immunization Schedule (2020-21) and Update on Immunization for Children Aged 0 Through 18 Years.Indian Pediatr. 2021 Jan 15;58(1):44-53. doi: 10.1007/s13312-021-2096-7. Epub 2021 Nov 29. Indian Pediatr. 2021. PMID: 33257602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical